News Archive

The Patient-Centered Outcomes Research Institute has funded up to $50 million to evaluate hydroxychloroquine as a preventive drug for the novel coronavirus.

When compared to patients with non-advanced heart failure, patients with advanced heart failure had a more than three-fold higher risk of dying within a year after receiving a defibrillator.

The award honors Douglas’ work in diversity and inclusion in the field of cardiology.

A novel composite risk model showed that 11 percent of sites had worse-than-expected performance, with patients experiencing higher rates of stroke, major bleeding, kidney injury, and paravalvular leak in the 30 days after undergoing a transcatheter aortic valve replacement.

The DCRI’s Manesh Patel, MD, who was a member of the steering committee for this late-breaking clinical trial, has been working for years to determine the best treatment strategies for patients with peripheral artery disease.

Recent evidence suggests that a novel oral anticoagulant plus a P2Y12 inhibitor may be the best treatment pathway for patients with atrial fibrillation undergoing percutaneous coronary intervention. DCRI faculty contributed to a meta-analysis recently published in JAMA Cardiology, which drew data from five clinical trials, including DCRI-led AUGUSTUS, to evaluate the safety and efficacy of four different antithrombotic regimens.

DCRI faculty Adrian Hernandez, MD, MHS, and Frank Rockhold, PhD, along with Duke Forge’s Eric Perakslis, PhD, contributed to a recently published paper in Science suggesting next steps that the National Institutes of Health (NIH) could take in order to expand its leadership in data sharing.

The coronavirus outbreak has limited in-person research, highlighting the need for more flexible, participant-friendly research models that can be conducted virtually.

Former FDA Commissioners Mark McClellan, MD, PhD, director of the Duke-Margolis Center for Health Policy, and Scott Gottlieb, MD, made recommendations for how the FDA should respond to the novel co

A paper recently published in JAMA Cardiology details the design of ADAPTABLE, a DCRI-led pragmatic clinical trial that uses many novel elements to efficiently answer a question that has substantial impacts on public health. ADAPTABLE seeks to determine the optimal dose of aspirin for patients with heart disease. Although aspirin has been used as a secondary prevention method for nearly three decades, the question of whether low-dose or high-dose aspirin is more beneficial remains unanswered.